Capecitabine in Low Risk Triple Negative Breast Cancer
This study aims to evaluate the efficacy and safety of capecitabine as the only adjuvant chemotherapy drug in patients with low-risk early triple-negative breast cancer who have received adequate local treatment. Patients meeting the inclusion criteria will receive capecitabine metronomic therapy for one year.
Breast Cancer
DRUG: Capecitabine
RFS, recurrence free survival, 3 years
iDFS, invasive disease-free survival, 3 years|DRFS, distant relapse-free survival, 3 years|DFS, disease-free survival, 3 years|OS, overall survival, 3 years|adverse events, adverse events according to CTCAE 5.0, 3 years|PRO, patient reported outcome, 3 years
This study aims to evaluate the efficacy and safety of capecitabine as the only adjuvant chemotherapy drug in patients with low-risk T1N0M0 early triple-negative breast cancer who have received adequate local treatment. Patients meeting the inclusion criteria will receive capecitabine metronomic therapy for one year. The low-risk population defined in this study includes the IM subtype with abundant stromal tumor-infiltrating lymphocytes, or the LAR subtype with low ki-67 proliferation, or elderly patients.